3.43
Voyager Therapeutics Inc stock is traded at $3.43, with a volume of 611.73K.
It is up +2.08% in the last 24 hours and up +8.54% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$3.36
Open:
$3.38
24h Volume:
611.73K
Relative Volume:
0.82
Market Cap:
$190.26M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
5.2769
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-8.04%
1M Performance:
+8.54%
6M Performance:
-18.72%
1Y Performance:
-48.58%
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VYGR
Voyager Therapeutics Inc
|
3.43 | 213.00M | 163.78M | 25.88M | -28.66M | 0.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
Dec-02-24 | Initiated | Citigroup | Buy |
Nov-29-24 | Resumed | Wedbush | Outperform |
Oct-16-24 | Initiated | Leerink Partners | Outperform |
Mar-26-24 | Initiated | Guggenheim | Buy |
Mar-19-24 | Initiated | H.C. Wainwright | Buy |
Mar-07-24 | Initiated | Citigroup | Buy |
Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
May-10-23 | Initiated | Truist | Buy |
Mar-10-23 | Initiated | Oppenheimer | Outperform |
Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Mar-19-20 | Initiated | The Benchmark Company | Buy |
Feb-06-20 | Initiated | Oppenheimer | Outperform |
Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-10-18 | Resumed | BTIG Research | Buy |
Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-04-18 | Initiated | H.C. Wainwright | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
Feb-02-18 | Initiated | Morgan Stanley | Overweight |
Nov-28-17 | Resumed | Piper Jaffray | Overweight |
Oct-31-17 | Initiated | Robert W. Baird | Outperform |
Oct-27-17 | Initiated | Canaccord Genuity | Buy |
Oct-23-17 | Reiterated | Stifel | Buy |
Oct-12-17 | Initiated | Raymond James | Outperform |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Trend Reversal Possible in Voyager Therapeutics Inc. Charts IndicateJuly 2025 Big Picture & Fast Exit/Entry Strategy Plans - beatles.ru
Is Voyager Therapeutics Inc. the Top Chart Pick This WeekLayoff News & Risk Managed Trade Strategies - newsyoung.net
Voyager Therapeutics Inc. Price Holds Above Key Fib LevelGold Moves & Low Drawdown Investment Ideas - beatles.ru
Analysts Spot Bullish Divergence in Voyager Therapeutics Inc.Quarterly Profit Report & Entry Point Confirmation Signals - thegnnews.com
What makes Voyager Therapeutics Inc. stock price move sharply2025 Key Highlights & Safe Capital Growth Stock Tips - thegnnews.com
Can Voyager Therapeutics Inc. Bounce Back From Weekly LowPortfolio Update Summary & Step-by-Step Swing Trade Plans - kangso.co.kr
Technical Charts Suggest Momentum Shift in Voyager Therapeutics Inc.Bull Run & Community Consensus Stock Picks - sundaytimes.kr
Voyager Therapeutics: Strategic Positioning and Promising Pipeline Drive Buy Rating - AInvest
Chart Analysts Warn of Resistance Near Voyager Therapeutics Inc. PriceMarket Trend Summary & Stepwise Trade Signal Guides - sundaytimes.kr
RSI + MACD Show Convergence for Voyager Therapeutics Inc.Capital Growth Entry Forecast Summary - beatles.ru
A Quick Look at Today's Ratings for Voyager Therapeutics(VYGR.US), With a Forecast Between $8 to $18 - 富途牛牛
Voyager Therapeutics Extends Cash Runway to 2028 - TipRanks
Wedbush Lowers Voyager Therapeutics (NASDAQ:VYGR) Price Target to $8.00 - MarketBeat
Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates - MSN
Voyager Therapeutics: Strategic Restructuring and Pipeline Progress Underpin Buy Rating - TipRanks
Voyager Therapeutics Inc. stock trend forecastStock Holding Strategy Long-Term Summary Sheet - Newser
Voyager Therapeutics: Strong Financial Position and Promising Pipeline Drive Buy Rating - TipRanks
Voyager Therapeutics: Wedbush Downgrades to Outperform, PT to $8 from $9 - AInvest
Voyager Therapeutics Q2 Earnings: A $33.4 Million SetbackNews and Statistics - IndexBox
Voyager Therapeutics 2025 Q2 Earnings Deepened Losses Amid Extended Cash Runway - AInvest
Voyager Reports Second Quarter 2025 Financial and Operating Results - The Manila Times
Voyager Therapeutics Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Voyager Therapeutics: Q2 Earnings Snapshot - News-Times
Voyager Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Voyager Therapeutics Q2 collaboration revenue drops, extends cash runway to 2028 - TradingView
Voyager Therapeutics Q2 2025 Financial and Operating Results - TradingView
MarineMax (HZO) adds Odilon Almeida Jr.; two directors resign – 8-K | VYGR SEC FilingForm 8-K - Stock Titan
What is the risk reward ratio of investing in Voyager Therapeutics Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
What drives Voyager Therapeutics Inc. stock priceTurbocharged investment results - Jammu Links News
Is Voyager Therapeutics Inc. stock overvalued or undervaluedFree Stock Index Interpretation - Jammu Links News
What analysts say about Voyager Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What are the technical indicators suggesting about Voyager Therapeutics Inc.Outstanding investment returns - Jammu Links News
How does Voyager Therapeutics Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
What are the latest earnings results for Voyager Therapeutics Inc.Maximize portfolio value with smart investment plans - Jammu Links News
What are Voyager Therapeutics Inc. company’s key revenue driversMaximize returns with effective portfolio management - Jammu Links News
What catalysts could drive Voyager Therapeutics Inc. stock higher in 2025Achieve consistent profits with disciplined trading - Jammu Links News
What are analysts’ price targets for Voyager Therapeutics Inc. in the next 12 monthsHigh-impact investment strategies - Jammu Links News
Should I hold or sell Voyager Therapeutics Inc. stock in 2025Consistent high-performance stocks - Jammu Links News
What is the dividend policy of Voyager Therapeutics Inc. stockFree Stock Market Knowledge Sharing - Jammu Links News
How many analysts rate Voyager Therapeutics Inc. as a “Buy”Wealth Building Data Feed For Every Investor - jammulinksnews.com
Is Voyager Therapeutics Inc. forming a bottoming baseStock Market Entry Timing Signals Revealed - metal.it
How does Voyager Therapeutics Inc. compare to its industry peersExpert Picks Tracker From AI Tools - Jammu Links News
Voyager Therapeutics Inc. Added to High Probability Setup ListBuy Signal Based on Chart Analysis Confirmed - metal.it
Voyager Therapeutics Inc. Tests 50 Day MA After Sharp DeclineQuick Gain Stock Watch With Indicators Reviewed - metal.it
Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest
Pattern Scan Adds Voyager Therapeutics Inc. to WatchlistMarket Entry and Exit Point Tips From Traders - metal.it
Published on: 2025-07-29 08:53:38 - metal.it
Is Voyager Therapeutics Inc. a growth stock or a value stockAI Powered Target Finder For Consistent Profits - jammulinksnews.com
Top Risks to Consider Before Buying Voyager Therapeutics Inc. StockPortfolio Diversification Stock Ideas From Experts - metal.it
What institutional investors are buying Voyager Therapeutics Inc. stockPost Market Review For 2025 - Jammu Links News
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):